Loading…
No business profile yet.
Size 6467 (6467.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $368M, the 546th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$224.50 on 18 Nov 2026.
Growth The operating margin is -2,617.6% (peer median -2.6%).
Valuation It trades at 1,407.9× enterprise value to sales against a peer median of 3.7× (most expensive of 18).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | NT$8.41M | NT$0 | NT$1.07M | NT$6.36M |
| Revenue growth | — | — | -100% | -83% | — |
| Gross profit | n/a | -NT$2.08M | -NT$6.99M | -NT$7.82M | -NT$3.88M |
| EBITDA | n/a | -NT$211M | -NT$163M | -NT$113M | -NT$57.8M |
| Net income | n/a | -NT$214M | -NT$167M | -NT$121M | -NT$66.3M |
| Free cash flow | n/a | -NT$209M | -NT$166M | -NT$107M | -NT$63.6M |
| Capital expenditure | n/a | NT$6.31M | NT$8.82M | NT$2.89M | NT$829,000 |
| Total debt | NT$8.56M | NT$11.3M | NT$16.7M | NT$53.6M | NT$32.0M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6467.TW | Peer median | Rank in peer set |
|---|---|---|---|
| Distance from 52-week high | -16.5% | -41.3% | 3rd highest of 21 |
| Operating margin | -2,617.6% | -2.6% | lowest of 18 |
| EV / Sales | 1,407.9× | 3.7× | most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | 1,407.9× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | 7.2× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | 4.9× | 22.2% | -15.7% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 3.0× | -7.9% | +24.8% |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | 5.3× | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | 1.6× | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 0.5× | 6.7% | +4.2% |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | 1.1× | 3.6% | +3.1% |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | n/a | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | 1.9× | 8.0% | -11.3% |